Skip to content

Studying the Effect of Freeze-Dried Table Grape Powder on Blood Estrogen Levels in Postmenopausal Women

Evaluation of the Aromatase Inhibition Potential of Standardized Grape Extract

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00611104
Enrollment
20
Registered
2008-02-08
Start date
2008-08-04
Completion date
2014-08-22
Last updated
2024-09-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Keywords

breast cancer

Brief summary

RATIONALE: Estrogen can cause the growth of breast cancer cells. Studying samples of blood and urine in the laboratory from participants receiving freeze-dried table grape powder may help doctors understand the effect of this drug on blood estrogen levels. PURPOSE: This clinical trial is studying the effect of freeze-dried table grape powder on blood estrogen levels in postmenopausal women.

Detailed description

OBJECTIVES: * To measure the change in levels of plasma estrone (E1), estradiol, E1-conjugates, and E1-sulfates in postmenopausal women after 6 weeks of daily ingestion of 94 grams of freeze-dried table grape powder. * To conduct bioavailability research on the freeze-dried table grape powder in humans through the analysis of participants' blood and urine samples. OUTLINE: Participants receive oral freeze-dried table grape powder once daily on days 1-42 in addition to their usual diet. Treatment continues in the absence of toxicity. Participants undergo blood sample collection at baseline, periodically after the first dose, and on the last day of the study for pharmacokinetic and bioavailability analysis. Samples are examined by mass spectrometry to measure plasma levels of estrone (E1), estradiol, E1-conjugates, E1-sulfates, testosterone, and androstenedione. Participants also undergo spot urine collection and weight and height measurement periodically during study. Participants complete food diaries on days 1-3, 21-23, and 40-42 to assess their intake of grapes, grape juice, and red wine and to examine the constancy of their caloric intake over the course of the study.

Interventions

DIETARY_SUPPLEMENTstandardized freeze-dried table grape powder
OTHERlaboratory biomarker analysis
OTHERpharmacological study

Sponsors

Mayo Clinic
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 120 Years
Healthy volunteers
Yes

Inclusion criteria

DISEASE CHARACTERISTICS: * Participant in the Mayo Mammography Health Study * Has consented to provide baseline mammogram for digitization PATIENT CHARACTERISTICS: * ECOG performance status 0-1 * Female * Postmenopausal (defined as women who have had both ovaries removed or no menstrual period for at least 12 consecutive months) * Able to give informed consent and complete food records alone or with assistance * Willing to provide research blood and urine samples * Must be a non-smoker * Willing to maintain current weight * No history of breast ductal carcinoma in situ or any other cancer, except basal cell or squamous cell skin cancer or lobular carcinoma in situ * No history of allergic or other adverse reaction to grapes * No history of diabetes or glucose intolerance PRIOR CONCURRENT THERAPY: * No concurrent hormone therapy, including estradiol, estrone, or progestins

Design outcomes

Primary

MeasureTime frame
Serum levels of plasma estrone (E1), estradiol, E1-conjugates, and E1-sulfates
Bioavailability of the freeze-dried table grape powder in humans

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026